Is 2552.HK overvalued or undervalued?

2552.HK currently has a P/E ratio of -18.63. Relative to the sector average of 26.80, this suggests the stock may be undervalued. A higher P/E than peers means investors are paying more for each unit of earnings, often because they expect faster future growth. However, if that growth does not materialize, the stock can appear overvalued. A lower P/E may indicate weaker growth expectations or higher risk, but it can also signal a potential valuation discount.

How can I buy Hua Medicine (Shanghai) Ltd. stock?

Hua Medicine (Shanghai) Ltd. trades on HKSE. Investors in Latin America can buy it through international and regional brokerage and investment platforms. You simply need a valid government ID or passport to get started.

Can I buy fractional shares of 2552.HK?

Yes. Through fractional investing, you can invest exactly the amount you want, starting with as little as $1 or $5 USD (depending on what investment platform you use), and own a proportional piece of the company.

Does buying 2552.HK protect my money against local inflation?

Many investors in Latin America buy international stocks like 2552.HK to protect their purchasing power. Because 2552.HK is priced in foreign currency, your investment is tied to a hard currency. If your local currency devalues against the foreign currency, usually USD or Euro, the underlying value of your stock portfolio remains protected from local inflation.

Do I need a foreign bank account or a Visa to buy 2552.HK shares?

No. A common misconception is that you need a foreign bank account or a foreign visa to invest in international stocks. Today, modern investment platforms allow you to fund your account using local bank transfers or local payment methods right from your home country.

Is 2552.HK a suitable investment for my portfolio?

There is no universal answer, since fit depends on your situation, not just the stock. Think about three things: how well 2552.HK diversifies what you already own, whether you can stomach its price swings given your risk tolerance, and how long you plan to stay invested. As a rule, a single stock works best as one piece of a broader asset allocation and with a multi-year time horizon. This is general information, not personalized financial advice.

All stocks2552.HK

Hua Medicine (Shanghai) Ltd.

HK$2.23-HK$0.06-2.62%

HKSE / HKD

Market cap

HK$2.2B

P/E

-18.6

EPS (TTM)

HK$-0.02

Dividend yield

0.00%

Beta

0.81

1Y return

-50.77%

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Compare, tap a companyup to 2 at once

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Financials

The numbers behind the company

Revenue vs net income

RevenueNet income

$02021

$3M2022

$11M2023

$35M2024

$69M2025

Financial health

Gross margin

Operating margin

ROE

ROA

Debt to equity0.36Low
Current ratio3.34
Cash ratio2.66
Net margin-16.5%
Free cash flow—

Valuation

Is it expensive right now

P/E vs the market

scale 0–50

0153050

2552.HK-18.6
Healthcare sector median26.8
S&P 50022.0

Trades about 170% below its sector, cheaper than its peers on earnings.

Ratios

PEG0.17
Price to book1.91
EPS (TTM)HK$-0.02
Payout ratio0%
FCF yield-2.18%

Range & risk

HK$1.97HK$4.03

Trading in the lower third of its 52-week band

Beta0.81

Profile

What Hua Medicine (Shanghai) Ltd. actually does

Hua Medicine (Shanghai) Ltd., a biopharmaceutical enterprise established in 2011 and headquartered in Beijing, China, specializes in the clinical development of novel therapeutic solutions, with a primary focus on addressing diabetes within the Chinese market. Its lead asset, Dorzagliatin (also known as HMS5552), is an orally administered medication designed for Type 2 Diabetes. The company is also advancing various combination therapies involving Dorzagliatin for T2D, including pairings with Metformin, Sitagliptin, and Empagliflozin, all of which are currently undergoing Phase I clinical trials. Furthermore, Hua Medicine explores the potential of Dorzagliatin in combination with Pioglitazone for Non-alcoholic steatohepatitis (NASH), with GLP-1 for Alzheimer's disease, and for applications in late-stage Type 2 Diabetes and Type 1 Diabetes. Beyond its diabetes pipeline, the company is developing mGLUR5 as a potential treatment for levodopa-induced dyskinesia in Parkinson's disease patients.

CEO

Li Chen

Employees

424

Headquarters

Shanghai, SH

Founded

2018-09-14

Company website

If you had invested a decade ago

Loading the full price history…

Run your own numbers

Past performance is not a forecast.

ETFs

Own it inside an ETF instead

Vanguard S&P 500

Vanguard Total Stock Market

Vanguard Total World Stock

Invesco QQQ

SPDR S&P 500

iShares Russell 2000

Community sentiment

Bullish—

Distribution

Bearish0%
Neutral0%
Bullish0%

Track it without buyingTrack it

no account needed

Save 2552.HK and get told when something moves.

Get updates

A clear, direct weekly summary.

Keep looking

Q&A

Questions people ask

2552.HK has a beta of 0.81, which indicates how sensitive it has historically been to movements in its broader market. A beta below 1 indicates lower relative volatility than the market. Beta is based on historical data and does not predict future performance.

Hua Medicine (Shanghai) Ltd.